CobimetinibCobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Sponsor:

Carl Allen

Code:

NCT04079179

Conditions

Langerhan's Cell Histiocytosis

Juvenile Xanthogranuloma

Erdheim-Chester Disease

Rosai Dorfman Disease

Neuro-Degenerative Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Cobimetinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Carl Allen on 2025-09-18.